Navigation Links
Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Date:5/6/2012

Philadelphia, PA, May 7, 2012 While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge. Researchers from the University of Pittsburgh School of Medicine have found that a genetic abnormality known as copy number variation (CNV) in prostate cancer tumors, as well as in the benign prostate tissues adjacent to the tumor and in the blood of patients with prostate cancer, can predict whether a patient will experience a relapse, and the nature of the relapse aggressive or indolent. Their report is published in the June issue of The American Journal of Pathology.

Copy number variations are large areas of the genome with either duplicated or missing sections of DNA. "Our analysis indicates that CNV occurred in both cancer and non-cancer tissues, and CNV of these tissues predicts prostate cancer progression," says lead investigator Jian-Hua Luo, MD, PhD, associate professor in the Divisions of Molecular and Cellular Pathology, and Anatomic Molecular Pathology, Department of Pathology, University of Pittsburgh School of Medicine. "Prediction models of prostate cancer relapse, or of the rate of PSA level increase after surgery, were generated from specific CNV patterns in tumor or benign prostate tissues adjacent to cancer samples."

To detect the abnormalities, scientists conducted a comprehensive genome analysis on 238 samples obtained from men undergoing radical prostatectomy: 104 prostate tumor samples, 85 blood samples from patients with prostate cancer, and 49 samples of benign prostate tissues adjacent to a tumor. A third of the samples were from patients exhibiting recurrence with a PSA level increasing at a rapid rate, doubling in less than four months (rapid increases are associated with lethal prostate cancer); a third from patients exhibiting recurrence with a PSA level increasing at a slow rate, doubling time greater than 15 months; and a third with no relapse more than five years after surgery. Three commercially available prostate cancer cell lines were also tested to validate the results.

Deletions of large segments of specific chromosomes occurred with high frequency, whereas amplification of other chromosomes occurred in only a subset of prostate cancer samples. Similar amplification and deletion of the same regions also occurred in benign prostate tissue samples adjacent to the cancer. Prostate cancer patients' blood was found to contain significant CNVs. Most were not unique and overlapped with those of prostate cancer samples.

Using gene-specific CNV from tumor, the model correctly predicted 73% of cases for relapse and 75% of cases for short PSA doubling time. The CNV model from tissue adjacent to the prostate tumor correctly predicted 67% of cases for relapse and 77% of cases for short PSA doubling time. Using median-size CNV from blood, the genome model correctly predicted 81% of the cases for relapse and 69% of the cases for short PSA doubling time.

Dr. Luo notes that there are several potential clinical applications using CNV tests. "For a patient diagnosed with prostate cancer, CNV analysis done on blood or normal tissues would eliminate the need for additional invasive procedures to decide a treatment mode. For a patient already having a radical prostatectomy, CNV analysis on the tumor or blood sample may help to decide whether additional treatment is warranted to prevent relapse. Despite some limitations, including the need for high quality genome DNA, CNV analysis on the genome of blood, normal prostate, or tumor tissues holds promise to become a more efficient and accurate way to predict the behavior of prostate cancer."


'/>"/>

Contact: David Sampson
ajpmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Some women may be genetically predisposed to smoking-related hot flashes
2. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
3. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
4. Research Gets Closer to Genetic Roots of Glaucoma
5. Genetic variants, tobacco exposure and lung cancer risk
6. Study of half siblings provides genetic clues to autism
7. Certain Genetic Regions May Be Tied to Osteoporosis
8. Head, Body Lice Are Genetically Very Similar
9. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
10. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
11. Genetic causes found in nearly 1 in 5 patients with dilated cardiomyopathy heart failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Texas Premier Locksmith ... carried out by unethical locksmith companies and is urging Search Engines to improve ... to Texas Premier Locksmith, these fraudulent locksmith services take advantage of consumers locked ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is honored ... under the Best New Product Launch category. Gensuite’s entry on their EZ Scan ... BOC Global Events & Training Group is a professional event and training provider ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To ... bringing greatness back to the presidency and to America. “Tomorrow Trump Goes To Washington” ... as much as she can for this country. , Nancy attributes her patriotic nature ...
(Date:12/7/2016)... ... 2016 , ... The Business Architecture Guild is ... on March 21-22, 2017. This premier event features business practitioners and experts from ... of industries such as financial services, insurance, healthcare, manufacturing, transportation, retail, and utilities. ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... that can be seen on a type of MRI, according to a study ... disorder of the central nervous system characterized by tremors or trembling and stiffness ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016 According to responses ... more than one-third (38%) of patients with non-small cell lung ... growth factor receptor (EGFR) genetic mutation status. The findings of ... LBA ID #6067 #P3.02b ) at the 2016 ... Austria . The survey results revealed an ...
(Date:12/7/2016)... Boehringer Ingelheim today announced that the ... malignant pleural mesothelioma (MPM) met its primary endpoint ... the 17 th IASLC World Conference on ... showed nintedanib plus pemetrexed/cisplatin demonstrated a meaningful clinical ... significantly improved PFS (9.4 vs 5.7 months). Preliminary ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
Breaking Medicine Technology: